Syndax Pharmaceuticals (SNDX) Competitors $15.01 +0.16 (+1.08%) Closing price 04:00 PM EasternExtended Trading$15.13 +0.12 (+0.80%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX vs. TGTX, PTCT, KRYS, ACLX, ARWR, ACAD, MENS, PCVX, PTGX, and ADMAShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arcellx (ACLX), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), Jyong Biotech (MENS), Vaxcyte (PCVX), Protagonist Therapeutics (PTGX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Its Competitors TG Therapeutics PTC Therapeutics Krystal Biotech Arcellx Arrowhead Pharmaceuticals ACADIA Pharmaceuticals Jyong Biotech Vaxcyte Protagonist Therapeutics ADMA Biologics TG Therapeutics (NASDAQ:TGTX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment. Do insiders and institutionals hold more shares of TGTX or SNDX? 58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to TGTX or SNDX? In the previous week, TG Therapeutics had 10 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for TG Therapeutics and 8 mentions for Syndax Pharmaceuticals. TG Therapeutics' average media sentiment score of 0.48 beat Syndax Pharmaceuticals' score of 0.07 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate TGTX or SNDX? TG Therapeutics presently has a consensus target price of $48.00, suggesting a potential upside of 35.55%. Syndax Pharmaceuticals has a consensus target price of $39.22, suggesting a potential upside of 161.31%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is TGTX or SNDX more profitable? TG Therapeutics has a net margin of 13.31% compared to Syndax Pharmaceuticals' net margin of -428.48%. TG Therapeutics' return on equity of 26.05% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics13.31% 26.05% 9.58% Syndax Pharmaceuticals -428.48%-130.47%-56.12% Which has better earnings and valuation, TGTX or SNDX? TG Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329M17.08$23.38M$0.3795.70Syndax Pharmaceuticals$77.93M16.59-$318.76M-$3.89-3.86 Which has more risk and volatility, TGTX or SNDX? TG Therapeutics has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. SummaryTG Therapeutics beats Syndax Pharmaceuticals on 13 of the 17 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$3.11B$5.74B$10.35BDividend YieldN/A2.36%5.53%4.58%P/E Ratio-3.8620.9076.3526.43Price / Sales16.59254.49466.9890.96Price / CashN/A46.3537.4661.85Price / Book4.449.8313.186.39Net Income-$318.76M-$52.73M$3.29B$271.22M7 Day Performance1.76%4.85%2.50%2.79%1 Month Performance-7.57%6.37%4.60%7.35%1 Year Performance-17.89%19.15%73.81%29.74% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals3.9165 of 5 stars$15.01+1.1%$39.22+161.3%-17.2%$1.29B$77.93M-3.86110Positive NewsTGTXTG Therapeutics4.3521 of 5 stars$32.37+1.0%$48.00+48.3%+53.0%$5.14B$329M87.49290PTCTPTC Therapeutics3.9012 of 5 stars$61.13+0.8%$69.00+12.9%+64.8%$4.85B$806.78M8.751,410Positive NewsKRYSKrystal Biotech4.9415 of 5 stars$156.84+1.8%$209.00+33.3%-8.4%$4.54B$290.52M31.88210Positive NewsACLXArcellx2.2775 of 5 stars$78.71+3.0%$114.31+45.2%-7.9%$4.37B$107.94M-23.0180ARWRArrowhead Pharmaceuticals4.1371 of 5 stars$30.60+5.0%$43.14+41.0%+62.5%$4.23B$572.98M-23.91400ACADACADIA Pharmaceuticals4.3504 of 5 stars$24.55+1.4%$29.65+20.8%+44.9%$4.14B$957.80M18.44510Trending NewsAnalyst ForecastOptions VolumeGap DownTrading HaltedMENSJyong BiotechN/A$54.00+0.5%N/AN/A$4.11BN/A0.0031Gap DownPCVXVaxcyte1.9537 of 5 stars$31.59+2.3%$106.25+236.4%-70.4%$4.10BN/A-7.69160PTGXProtagonist Therapeutics1.6194 of 5 stars$61.85+4.4%$68.08+10.1%+41.0%$3.85B$434.43M88.35120ADMAADMA Biologics3.2744 of 5 stars$15.87+2.0%$27.67+74.4%-20.2%$3.79B$474.17M18.45530 Related Companies and Tools Related Companies TGTX Alternatives PTCT Alternatives KRYS Alternatives ACLX Alternatives ARWR Alternatives ACAD Alternatives MENS Alternatives PCVX Alternatives PTGX Alternatives ADMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNDX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.